A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in patients with platinum-resistant recurrent ovarian, tubal o...

Full description

Saved in:

Bibliographic Details
Published in:	Gynecologic oncology Vol. 151; no. 3; pp. 422 - 427
Main Authors:	Monk, Bradley J., Kauderer, James T., Moxley, Katherine M., Bonebrake, Albert J., Dewdney, Summer B., Secord, Angeles Alvarez, Ueland, Frederick R., Johnston, Carolyn M., Aghajanian, Carol
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.12.2018
Subjects:	Adult Aged Aged, 80 and over Antineoplastic Agents, Phytogenic - pharmacology Antineoplastic Agents, Phytogenic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical trial Elesclomol Fallopian Tube Neoplasms - drug therapy Fallopian Tube Neoplasms - pathology Female Humans Hydrazines - pharmacology Hydrazines - therapeutic use Middle Aged Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Paclitaxel - pharmacology Paclitaxel - therapeutic use Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - pathology Clinical trial Elesclomol Ovarian cancer
ISSN:	0090-8258, 1095-6859, 1095-6859
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!